Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (NYSE: COO) reported fiscal Q3 results for the period ending July 31, 2022. Revenue rose 10% year-over-year to $843.4 million. CooperVision revenue increased 2% to $566.3 million, while CooperSurgical surged 35% to $277.1 million. GAAP diluted earnings per share fell to $1.98, down from $12.37 a year prior. Non-GAAP diluted EPS was $3.19, a decline of 6%. The company expects FY 2022 revenues between $3.29 - $3.31 billion. CEO Al White emphasized strong demand and successful strategic initiatives to enhance shareholder value.
CooperCompanies (NYSE: COO) will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 1:20 PM ET. President and CEO Al White will represent the company in this session. Interested parties can access a live webcast through the investor relations website. A replay will also be available post-event. Based in San Ramon, California, CooperCompanies operates globally with over 12,000 employees and offers a wide range of products through its divisions, CooperVision and CooperSurgical, serving over 100 countries.
CooperCompanies (NYSE: COO) has appointed Nicholas Khadder as its new general counsel and corporate secretary, effective immediately. Khadder brings extensive legal experience, having previously served as general counsel at Standard BioTools Inc. from June 2016 to July 2022 and held several senior roles at Amyris, Inc. and other companies. He holds a Juris Doctor from Berkeley Law. This leadership change is expected to enhance the company's legal strategy and governance.
CooperCompanies (NYSE: COO) will announce its third quarter 2022 financial results on August 31, 2022, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss the results and other corporate developments. Participants can register for the call through a provided link and listen to a simultaneous webcast available on their website. Cooper, headquartered in San Ramon, CA, operates through CooperVision and CooperSurgical, employing over 12,000 people and selling products in more than 100 countries.
CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, payable on August 11, 2022, to stockholders of record on July 27, 2022. This move aligns with the company’s board-approved strategy to distribute annual dividends. CooperCompanies operates through CooperVision and CooperSurgical, focusing on vision care and women's health products, respectively. The company is headquartered in San Ramon, CA, and employs over 12,000 people globally, with sales in more than 100 countries.
CooperCompanies (NYSE: COO) reported a 15% year-over-year revenue increase to $829.8 million for its fiscal second quarter ending April 30, 2022. CooperVision revenue rose 6% to $553.8 million, while CooperSurgical surged 40% to $276.0 million. GAAP diluted EPS was $2.55, up $0.19, while non-GAAP diluted EPS fell 4% to $3.24. Operating margin decreased to 16% from 20% due to currency effects. The company updated fiscal 2022 revenue guidance to $3,280 - $3,312 million.
CooperVision has appointed Alex Wilkes as President of the Americas, effective June 14, 2022. Wilkes, with over a decade of experience in the eye care industry, previously served as Senior VP and GM of Pearle Vision at Luxottica. He will oversee growth strategies for the U.S., Canada, and Latin America. Mark Harty, EVP and Chief Commercial Officer, emphasized Wilkes' success in driving growth and market strategies. Wilkes expressed enthusiasm about joining CooperVision, aligning with its values and innovative product direction.
CooperCompanies (NYSE: COO) will participate in the Jefferies Healthcare Conference on June 9, 2022, at 1:00 PM ET. Al White, the President and CEO, will represent the company during this session.
The event can be accessed via CooperCompanies’ website, with a replay available 48 hours post-event. CooperCompanies is a global medical device firm operating through CooperVision and CooperSurgical, focusing on vision care and women's health products. Headquartered in San Ramon, CA, the company employs over 12,000 people and sells products in more than 100 countries.
CooperCompanies (NYSE: COO) has published its 2021 ESG Highlights Report, detailing ESG progress relevant to stakeholders. Highlights include a 100% score on the Human Rights Campaign’s Corporate Equality Index, gender parity on the Board, and 35% ethnic diversity in the workforce. Cooper became a participant in the UN Global Compact initiative.
CooperCompanies (NYSE: COO) announced that it and Cook Medical received a second request from the FTC regarding the acquisition of Cook Medical’s Reproductive Health business. This request, part of the HSR Act's regulatory process, extends the waiting period until compliance is achieved. The companies are collaborating with the FTC and anticipate closing the deal by the end of 2022.
Cooper operates two business units: CooperVision and CooperSurgical, focusing on medical devices and fertility solutions.